Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant - PA: Breast Cancer Research

Université Laval

$100,000.00

The Ribosomal RNA Genes in Growth, Pluripotency, Senescence and Cancer

FY 2023-24

Summary
Building the cell's protein factories is a complex job involving many hundreds of components and takes up much of a cell's efforts to grow. For cancers to grow, they must find ways to make more of these protein factories than the surrounding normal tissues. So, if we could find ways to limit the manufacture the protein factories, known as ribosomes, we could control cancer. Though this sounds simplistic, we have recently demonstrated in model systems that targeting the genes that make the RNAs of the ribosome kills cancer cells while leaving normal cells untouched. We also identified known and novel chemo-drugs that already in fact act in this way, and "tumour suppressor" proteins that prevent cancer in a similar ways. For example, the ARF and TP53 tumour suppressors are very important in limiting ribosome production and either or both are inactivated in 80% of cancers. However, these activities have in the main part been overlooked in the rush to identify cancer causing genes. In large part this has been due to the perceived complexity of making ribosomes but also because the key genes involved are omitted from all bioinformatic searches for genetic signatures of cancer. Our studies over the last years have attempted correct this by directly studying the links between cancer and ribosome production. We propose to continue to develop this work by delving into the mechanisms underlying Breast Cancer, Liver and Colorectal Cancers and Acute Myeloid Leukemia, the factors that control Tumour Suppression and the actions of novel Drug Therapies.
Program
Project Grant - PA: Breast Cancer Research
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
494928
Name
Moss Thomas
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Biochemistry & Molecular Biology - B
Projecttitle
The Ribosomal RNA Genes in Growth, Pluripotency, Senescence and Cancer
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Breast Cancer Research
Keyworddelim
Cancer Cell Lines; Chemotherapeutics; Epigenetic Regulation; Human Cancer; Pluripotency; Ribosomal Rna Genes (Rn18s, Rn28s, Rn5-8s); Rna Polymerase I (Rpi/Poli/Polr1); Senescence; Transcriptional Regulation; Tumour Suppression
Abstract
Building the cell's protein factories is a complex job involving many hundreds of components and takes up much of a cell's efforts to grow. For cancers to grow, they must find ways to make more of these protein factories than the surrounding normal tissues. So, if we could find ways to limit the manufacture the protein factories, known as ribosomes, we could control cancer. Though this sounds simplistic, we have recently demonstrated in model systems that targeting the genes that make the RNAs of the ribosome kills cancer cells while leaving normal cells untouched. We also identified known and novel chemo-drugs that already in fact act in this way, and "tumour suppressor" proteins that prevent cancer in a similar ways. For example, the ARF and TP53 tumour suppressors are very important in limiting ribosome production and either or both are inactivated in 80% of cancers. However, these activities have in the main part been overlooked in the rush to identify cancer causing genes. In large part this has been due to the perceived complexity of making ribosomes but also because the key genes involved are omitted from all bioinformatic searches for genetic signatures of cancer. Our studies over the last years have attempted correct this by directly studying the links between cancer and ribosome production. We propose to continue to develop this work by delving into the mechanisms underlying Breast Cancer, Liver and Colorectal Cancers and Acute Myeloid Leukemia, the factors that control Tumour Suppression and the actions of novel Drug Therapies.
Competitiondate
202309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Moss, Thomas
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
Université Laval - $100,000 Grant (2023-24) | Canada Spends